We are determined to help people living with neurological disorders through the development of innovative solutions and potential new treatments. We currently have approved therapies for patients with relapsing multiple sclerosis, and our scientists are deploying an array of technologies to develop new potential treatments that may help address the underlying cause of disease. Additionally, Neurology is an area of continued focus on innovation with research in key areas including Myasthenia gravis, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and other neurological diseases.

Anita, Multiple Sclerosis, Norway

Did you know


Neurological disorders are the leading cause of disability and second leading cause of death globally.1

~2.9 million

people worldwide are estimated to live with multiple sclerosis (MS).2


Someone is diagnosed with or passes away from amyotrophic lateral sclerosis (ALS) every 90 minutes.3

Cassie, multiple sclerosis, Australia
Cassie, multiple sclerosis, Australia

Our commitment to neurology

We’re taking on the complex challenges of neurological diseases, advancing scientific understanding and developing treatments to address long-unmet needs.

Since 2012, we’ve been working to improve the lives of people with serious neuro-degenerative diseases. Our pipeline medicines aim to address MS, ALS, Parkinson’s disease (PD), and chronic inflammatory demyelinating polyradiculoneuropathy.

Dave, multiple sclerosis, United Kingdom
Dave, multiple sclerosis, United Kingdom

Our neurology focus

Our neurology programs are built on a strong foundation of long-term partnerships with patients, physicians, advocates and researchers. Our goal is to slow or even halt neurodegeneration in MS, ALS, PD, and other neurological diseases.


  1. Feigin V, Vos T, Nichols E, et al. (2019). The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 19:255-265; DOI: 10.1016/S1474-4422(19)30411-9 
  2. Multiple Sclerosis International Federation (2023). Atlas of MS. Accessed July 2023
  3. ALS Association (2021). Helping You Understand ALS. Accessed October 2022